Scinai Immunotherapeutics Ltd. Announces Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has published peer-reviewed data in the Journal of Dermatological Treatment, highlighting PC111's potential as a disease modifier for pemphigus and SJS/TEN, offering a new, non-immunosuppressive treatment approach.
